Key clinical message: There is no effective treatment that reduces both the severity and duration of a common cold episode. SJP - 002 (naproxen and fexofenadine) reduced symptom severity by two-third, and the duration of the common cold episode approximately by half.
Abstract: The common cold is one of the most frequently experienced immune-related complaints. At present, available treatments have limited efficacy in inhibiting symptoms associated with upper respiratory tract infection, nor do they significantly shorten the duration of common cold episodes. Four case reports are presented of individuals with a common cold. Three of them self-administered the combination of naproxen and fexofenadine (SJP - 002). Results of one individual were compared to her spouse, who did not take SJP - 002 to treat common cold, while two other individuals took SJP - 002 and compared symptom severity with another common cold episode they experienced previously without taking SJP - 002. SJP - 002 reduced the severity of symptoms associated with upper respiratory tract infection by two-third and reduced the duration of the common cold episode approximately by half. In conclusion, SJP - 002 reduced the severity and duration of common cold episodes. These findings warrant further investigation of SJP - 002 in double-blind, placebo-controlled clinical trials.
Keywords: SJP − 002; common cold; fexofenadine; naproxen; rhinovirus; treatment; upper respiratory tract infection.
© 2023 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.